Posted by Michael Wonder on 31 Oct 2024
Foresee Pharmaceuticals announces submission of the NDA to the US FDA for the 3 month version of Camcevi for the treatment of advanced prostate cancer
30 October 2024 - Foresee Pharmaceuticals announced today that it has submitted a 505(b)(2) new drug application for the 3 month version of Camcevi, a ready to use 3 month depot formulation of leuprolide mesylate, to the US FDA.
The application seeks approval for the use of this product for the palliative treatment of advanced prostate cancer.
